Most unresectable metastatic colon cancer remains incurable, with a median survival of less than 3 years. Molecularly targeted therapies have recently been developed; in particular, monoclonal antibodies against the epidermal growth factor receptor, which are efficacious in 40% to 60% of chemotherapy-resistant patients with wild-type KRAS. This study shows that cetuximab plus irinotecan, compared with cetuximab alone, increases the response rate and delays progression in irinotecan-resistant RAS wild-type colorectal cancer. progression-free survival; secondary endpoints were response rate, overall survival, toxicity, and quality of life.
Introduction
Colorectal cancer is the fourth leading cause of cancer mortality globally.
1 Unresectable, metastatic colorectal cancer is treated with systemic cytotoxic therapy and biologic agents. Despite stepwise advances over the last 20 years, most disease remains incurable, with median survival less than 3 years and few patients surviving longer than 5 years. 2, 3 Identification of prognostic and predictive molecular biomarkers has allowed therapy to be tailored, in particular by using a class of monoclonal antibodies that target the epidermal growth factor receptor (EGFR). Multiple retrospective series determined that their efficacy is restricted to patients with tumors that are wild-type (no mutations) for exon 2 of the KRAS gene. [4] [5] [6] [7] Subsequently, benefit was found to be further restricted to tumors also wild-type for KRAS exons 3 and 4 and NRAS exons 2, 3, and 4. [8] [9] [10] [11] The EGFR monoclonal antibodies were initially used in patients with chemotherapy-resistant disease; the landmark CO-17 trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)eAustralasian GastroIntestinal Trials Group (AGITG) demonstrated that cetuximab, compared with best supportive care, in patients with wild-type KRAS (exon 2 only), improves progression-free survival (PFS) and also overall survival (OS) to a median of 9.5 months versus 4.8 months (hazard ratio [HR] , 0.55; 95% confidence interval [CI] , 0.41-0.74; P < .001). 7 Extended RAS mutation testing is now routinely performed to select the 40% of metastatic colorectal tumors that are all-RAS wild-type, and so suitable for the 2 currently available EGFR monoclonal antibodies (cetuximab and panitumumab). 12 Even among patients with all-RAS wild-type, chemotherapyresistant disease, only 40% to 60% respond to EGFR antibody treatment, 13 prompting interest in the predictive value of additional biomarkers downstream of the target in the MAP kinase and PI3 kinase pathways. Retrospective consortium analyses and systematic reviews have demonstrated that BRAF and PIK3CA mutations and nonfunctional PTEN mutations or loss of protein expression may predict resistance to EGFR therapy, concluding that "biomarker analyses beyond KRAS exon 2 should be implemented." [14] [15] [16] However, this remains clinically controversial, and practice varies as to whether patients with tumors harboring these other mutations are offered such therapy. At the time of devising the current study, standard practice was to exclude only patients with KRAS exon 2 tumor mutations. The AGITG Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) trial (ACTRN12612000901808) aimed to prospectively evaluate the efficacy of cetuximab in a highly molecularly selected population-a quadruple wild-type genotype (no mutations in KRAS, NRAS, BRAF, or P13KCA exon 20). The other part of the trial, evaluating cetuximab in 51 patients whose tumors harbored a G13D mutation in KRAS exon 2, has been published. 17 A further question of interest in the molecularly selected population is whether cetuximab might be more efficacious in combination with chemotherapy than as monotherapy. Efficacy of cetuximab was first demonstrated in unselected chemotherapyresistant metastatic colorectal cancers in the Bowel Oncology with Cetuximab Antibody (BOND) study. 18 Patients who had documented disease progression on irinotecan-based therapy were randomized to cetuximab alone or in combination with irinotecan. Those who received cetuximab and irinotecan had higher response rates and delayed disease progression. Despite this, after KRAS was identified as a biomarker for response to EGFR antibody treatment, several large phase III trials elected to use these drugs as monotherapy for resistant disease. [19] [20] [21] The ICECREAM trial assessed the efficacy of monotherapy compared with combination with chemotherapy in the molecularly selected quadruple wild-type population.
Patients and Methods
Patients were recruited at 13 hospitals in Australia. The study was performed in accordance with the Declaration of Helsinki. Central or institutional ethics and local research governance approval was required. All patients provided written informed consent. The protocol has been published. 22 Key eligibility criteria were: unre- ; and adequate marrow, hepatic, and renal function. Patients were required to have disease progression after standard therapy with (unless intolerant of) oxaliplatin and fluoropyrimidines. All patients were required to have documented progression within 6 months of receiving an irinotecan-containing regimen, but deemed still fit enough to receive further irinotecan.
Mutation Status
Quadruple wild-type status (no activating mutations in KRAS, NRAS, BRAF, or PI3KCA exon 20) was centrally confirmed at the Centre for Translational Pathology, University of Melbourne, Australia. DNA was derived from archival formalin-fixed, paraffinembedded tumor from the primary colorectal cancer or any metastatic site. Next-generation sequencing analysis targeted regions of interest from exon 15 of the BRAF gene, exons 9 and 20 of the PIK3CA gene, and exons 2, 3, and 4 of both KRAS and NRAS genes. The assay limit of detection was 5%, as published. 22 Cetuximab for Wild-type Colorectal Cancer mg/m 2 IV weekly, with or without 180 mg/m 2 irinotecan IV every 2 weeks. Treatment continued until disease progression, unmanageable toxicity, or a decision by the patient or clinician to stop. Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. 24 If toxicity was attributable to one particular drug, the other drug could be continued on schedule. Either drug could be delayed for a maximum of 28 days; if an adverse event (excluding skin toxicity and alopecia) had not then returned to grade 0, study treatment was permanently discontinued. An independent data and safety monitoring committee regularly assessed patient safety and trial progress.
Study Design and Treatment

Endpoints
The primary endpoint was the proportion of patients remaining free from progression, defined as the Kaplan-Meier estimate of patients without progressive disease at 6 months after random assignment (6-month PFS). Response was measured according to RECIST v1.1 criteria on the basis of 6-weekly computed tomography scans. Patients were censored on the date of last followup or at the start of non-protocol anticancer treatment. Secondary endpoints were: response rate, defined as the proportion of evaluable patients with a complete response or partial response; OS, measured from the date of random assignment to the date of death from any cause (patients still alive were censored at the date of last follow-up); quality of life, defined by scores on the global scale of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) 25 assessed at baseline and every 4 weeks until disease progression, the skin-specific Dermatology Life Quality Index 26 and Functional Assessment of Cancer Therapy Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) questionnaires, 27 assessed at baseline then weekly for 12 weeks or until disease progression; and toxicity. Statistical assumptions used Simon's 2-stage design 28 to establish that 25 patients would provide 80% power to rule out 30% 6-month PFS for cetuximab monotherapy, in favor of a clinically relevant rate of at least 58% for cetuximab plus irinotecan, at a level 0.05. As this study was comparing treatments that are considered standard of care, a formal futility analysis was considered unnecessary, and the protocol was amended to reflect this. Exploratory analyses comparing treatment groups for PFS and OS were described using HRs, and their associated 95% CIs were estimated by using Cox proportional-hazards models. Waterfall plots were constructed by using the biggest decrease from baseline in the sum of the target lesion measurements. Patients with a decreased sum of target lesions but with new nontarget lesions were set to a zero change but coded as having progressive disease. Response rates were compared using a c 2 test. Quality-of-life changes over time were modeled by using generalized estimating equations. Analyses used SAS software v9.3 (SAS Institute, Cary, NC).
Data Availability
ICECREAM trial data are not automatically available to other researchers. Proposals for analyses of these data or collaborative studies by other researchers are welcome. The ICECREAM dataset is held by the National Health and Medical Research Council Clinical Trials Centre, University of Sydney.
Results
Between November 2012 and June 2016, 48 patients with quadruple wild-type tumors were randomly assigned to cetuximab monotherapy or cetuximab plus irinotecan (Figure 1) . Two participants were later found to be ineligible; 1 was not irinotecanresistant according to definition, and 1 was found to have a BRAF mutation. Two of the 46 patients available for efficacy were not evaluable for response as they did not receive any study treatment. Baseline characteristics (Table 1) were balanced between the treatment arms, with the exception of gender (male, 62% vs. 72%) and primary disease site (left, 95% vs. 68%).
The median time on treatment for cetuximab monotherapy was 4.3 months compared with 5.9 months for cetuximab plus Table 2) . A median of 9 (cetuximab) versus 12.5 (cetuximab plus irinotecan) cycles of cetuximab was administered.
Primary Endpoint
The 6-month PFS rate was 14% (95% CI, 4%-32%) in the cetuximab arm and 41% (95% CI, 22%-60%) in the combination arm (HR, 0.39; 95% CI, 0.20-0.78; P ¼ .008) (Figure 2) . In a sensitivity analysis including the 2 ineligible patients, HR was 0.37 (95% CI, 0.19-0.73; P ¼ .004). The result of an analysis including only eligible patients and adjusting for the baseline imbalances of gender and sidedness was similar (HR, 0.37; 95% CI, 0.19-0.75; P ¼ .006).
Secondary Endpoints
Objective responses were achieved in 2 (10%) of 20 evaluable patients who received cetuximab and in 9 (38%) of 24 who received cetuximab plus irinotecan, including 1 complete response (difference in response rates, 28%; 95% CI, 4%-51%; P ¼ .04). In patients who received cetuximab, the best response was stable disease in 14 (70%), whereas 4 (20%) had progressive disease. In those treated with the combination, 11 (46%) had stable disease Cetuximab for Wild-type Colorectal Cancer and 4 (17%) had progressive disease. The best responses by treatment arm are shown in Figure 3 . At the time of data cut-off, 4 patients were still alive. The 6-month OS rates were 62% versus 76% (HR, 0.66; 95% CI, 0.35-1.23; P ¼ .19) (Figure 4) .
No new or unexpected toxicities were encountered (Table 2) . Less toxicity was observed with monotherapy: 23% versus 50% experienced at least 1 grade 3 or 4 adverse event, and 14% versus 42% had at least 1 serious adverse event. Most patients in the cetuximab arm ceased the study owing to disease progression, whereas more patients in the combination arm ceased because of patient or clinician preference. No significant differences in quality of life were observed between treatment arms ( Figure 5 ).
Discussion
This phase II trial demonstrates a significant response and PFS benefit for the addition of irinotecan to cetuximab in a highly molecularly selected population of patients with resistant colorectal cancer, echoing the BOND data generated in 2004 in an unselected population. 18 The importance of this finding relates to the widespread clinical practice of abandoning the addition of irinotecan to cetuximab since the identification of KRAS as a biomarker of response to EGFR monoclonal antibody therapy. Cetuximab monotherapy was used as the control arm in international phase III clinical trials such as the CO.17 and CO.20 studies. 19, 21 Trials with panitumumab in the resistant setting also used monotherapy as the standard arm. 20 On the other hand, Figure 3 Waterfall combination therapy had been uniformly adopted for earlier lines of treatment. Until the ICECREAM trial, the contention that EGFR antibody efficacy would not be enhanced by concurrent irinotecan in chemotherapy-resistant, RAS wild-type tumors had not been tested in a biomarker-selected, metastatic colorectal cancer population.
The impetus for ICECREAM arose from the real-life observation that, in Australia, there was an approximate 50/50 split between antibody monotherapy and combination treatment for resistant disease. A superselected group of likely responders to EGFR antibodies seemed to be an ideal setting in which to test the contribution of irinotecan to response in patients with resistant colorectal cancer. At the time of the trial conception in 2011, only KRAS exon 2 was used as a biomarker of response, although retrospective evidence was emerging of similar selectivity with extended KRAS testing (exons 3 and 4), as well as NRAS. Data on the predictive value of BRAF was less certain at the time and remains controversial, but overall, patients with tumors with BRAF mutations appear to derive less benefit from EGFR antibody treatment. To maximize recruitment, our study permitted the enrollment of patients whose disease had progressed within 6 months of irinotecan chemotherapy, whereas the BOND study required progression within 3 months of irinotecan. 18 Although EGFR antibodies were not publicly funded in Australia for earlier lines of therapy until near the end of the study, availability through clinical trials and access schemes posed a recruitment challenge. Nevertheless, the results of both trials are remarkably similar. In the BOND trial, 6-month PFS was 8% for monotherapy, improved to 30% with combination therapy; in ICECREAM this was 14%, improved to 41%. For response rate, the BOND study reported 11% versus 23%; we report here 10% versus 38%. The small numbers enrolled in our trial likely underplayed the benefit of superselection, as mutations in extended RAS testing are relatively infrequent. For the KRAS G13D-mutant arm of the ICECREAM study, we reported a similar improvement in 6-month PFS with the addition of irinotecan to cetuximab. 17 Coupled with the quadruple wild-type data, it appears that true synergy between irinotecan and cetuximab is likely, although we cannot exclude the notion that part of the observed irinotecan benefit derives from response of chemosensitive clones within a heterogeneous tumor. The HR of 0.66 for OS was at a clinically meaningful level, with the small sample size contributing to the survival difference not being statistically significant. The apparent extra benefit from the chemotherapy needs to be weighed against toxicity; although importantly, our study did not observe a difference in quality of life. In summary, data from this focused and strategic trial should be sufficient to inform practice, given its consistency with previous data and the reality that further examination in a phase III study is unlikely.
Conclusion
The AGITG ICECREAM trial confirms significant benefit for the addition of irinotecan to cetuximab, with improved PFS and increased response rate in patients with quadruple wild-type metastatic colorectal cancer. This echoes data in molecularly unselected patients and suggests that cetuximab is optimally used in combination with irinotecan for resistant colorectal tumors.
Clinical Practice Points
Monoclonal antibodies against the EGFR receptor have been shown to be efficacious in 405% to 60% of patients with chemotherapy-resistant colon cancer with wild-type RAS. Whether these antibodies should be used as a monotherapy or in combination with a chemotherapeutic agent in these patients remains an open question. This study shows that cetuximab plus irinotecan, compared with cetuximab alone, offers signicant benefit in this selected patient group, increasing the response rate and delaying progression in chemotherapy-resistant quadruple wild-type RAS colorectal cancer.
